Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era

被引：26

作者：

Nacci, Francesca ^{[1
,2
,3
]}

Matucci-Cerinic, Marco ^{[1
,2
,3
]}

机构：

[1] Med & Deno Ctr Univ Florence, Dept Rheumatol AVC, Florence, Italy

[2] Med & Deno Ctr Univ Florence, Dept Biomed, Florence, Italy

[3] Med & Deno Ctr Univ Florence, Div Rheumatol AOUC, Florence, Italy

来源：

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2011年 / 25卷 / 03期

关键词：

Anti-TNF-alpha; Tuberculosis; Infections; ACTIVE RHEUMATOID-ARTHRITIS; FACTOR MONOCLONAL-ANTIBODY; PATIENT-REPORTED OUTCOMES; PEGOL PLUS METHOTREXATE; HEPATITIS-B; LATENT TUBERCULOSIS; FACTOR ANTAGONISTS; DOUBLE-BLIND; MYCOBACTERIUM-TUBERCULOSIS; OPPORTUNISTIC INFECTIONS;

D O I：

10.1016/j.berh.2011.06.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We review the global experience of infections in patients treated with tumour necrosis factor (TNIF)-alpha inhibitors, which shows that the overall incidence of severe infections is at least doubled. In particular, this is true regarding tuberculosis. Screening and prophylactic measures have substantially reduced but not eliminated the risk. Recent improvements in immunologic testing for non-Bacillus Calmette Guerin (BCG)-related antigens allow more sensitive identification of latent tuberculosis and wider use of such methods holds promise as pre-treatment screening instruments. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：375 / 388

页数：14

共 118 条

[71]

Michel M, 2003, J RHEUMATOL, V30, P1624

[72] Subfulminant hepatitis B after infliximab in Crohn's disease: Need for HBV-screening? [J].

Millonig, Gunda ;

Kern, Michaela ;

Ludwiczek, Othmar ;

Nachbaur, Karin ;

Vogel, Wolfgang .

WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (06) :974-976

[73] Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor [J].

Mohan, AK ;

Coté, TR ;

Block, JA ;

Manadan, AM ;

Siegel, JN ;

Braun, MM .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) :295-299

[74]

MONSALVEDECASTI.F, 2002, IMMUNOLOGY, V9, P1372

[75] Specific detection of tuberculosis infection an interferon-γ-based assay using new antigens [J].

Mori, T ;

Sakatani, M ;

Yamagishi, F ;

Takashima, T ;

Kawabe, Y ;

Nagao, K ;

Shigeto, E ;

Harada, N ;

Mitarai, S ;

Okada, M ;

Suzuki, K ;

Inoue, Y ;

Tsuyuguchi, K ;

Sasaki, Y ;

Mazurek, GH ;

Tsuyuguchi, I .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (01) :59-64

[76] High Incidence of Anergy in Inflammatory Bowel Disease Patients Limits the Usefulness of PPD Screening Before Infliximab Therapy [J].

Mow, William S. ;

Abreu-Martin, Maria T. ;

Papadakis, Konstantinos A. ;

Pitchon, Howard E. ;

Targan, Stephan R. ;

Vasiliauskas, Eric A. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (04) :309-313

[77] Systemic Listeriosis With Adalimumab Therapy [J].

Murphy, Grainne ;

Schmidt-Martin, Daniel ;

Hynes, Brian Gerard ;

Harney, Sinead .

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2009, 15 (07) :369-370

[78] Reactivation of histoplasmosis after treatment with infliximab [J].

Nakelchik, M ;

Mangino, JE .

AMERICAN JOURNAL OF MEDICINE, 2002, 112 (01) :78-78

[79]

*NAT COLL CTR CHRO, TUB CLIN DIAG MAN TU

[80] Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection [J].

Nelson, DR ;

Lim, HL ;

Marousis, CG ;

Fang, JWS ;

Davis, GL ;

Shen, LP ;

Urdea, MS ;

Kolberg, JA ;

Lau, JYN .

DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (12) :2487-2494

← 3 4 5 6 7 8 9 10 11 12 →